E. Neutrophils in tuberculosis — first line of defence or booster of disease and targets for host-directed therapy? Pathog. Dis. 74, ftw012 (2016). Article PubMed Google Scholar Eum, S. Y. et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with ...
Prioritizing genes for translation to therapeutics for common diseases has been challenging. Here, we propose an approach to identify drug targets with high probability of success by focusing on genes with both gain of function (GoF) and loss of function (LoF) mutations associated with opposing eff...
First, autophagy generates energy efficiently via ATP synthesis in the mitochondria and maintains endoplasmic reticulum (ER) stress mediated by selective degradation of non-functional macromolecules and organelles. In contrast, the proteasome system consumes ATP. Second, the size of the protein targets ...
Antibody–drug conjugates in solid tumors: a look into novel targets Article Open access 28 January 2021 Potential of antibody–drug conjugates (ADCs) for cancer therapy Article Open access 13 August 2022 Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies...
Wu LJ, Kim SS, Zhuo M. Molecular targets of anxiety: from membrane to nucleus. Neurochem Res 2008;33:1925–1932. ArticleCAS Faludi G, Gonda X, Bagdy G, Dome P. Pharmaco- and therapygenetic aspects in the treatment of anxiety disorders beyond the serotonergic system: a brief review. Neur...
Furthermore, the growing knowledge on the microbiota as therapeutic targets and as a site of drug metabolism leads us to pay more attention to microbiota-mediated interactions when examining potential DDIs and HDIs. 4. Disease–drug interactions Understanding disease–drug interactions is clinically ...
Discovery and development of new medicines is a long and high-risk process that has become more costly and complex over time, as technology and scientific understanding of disease targets has improved. However, even among drug candidates reaching late-stage clinical development the probability of succ...
proteins and even antibodies, our understanding of TCM has similarly advanced in stages. We have moved from viewing TCM as a monomeric entity to recognizing the active protein components of TCMs and from considering only the symptoms that drugs address to the specific targets that drugs regulate [...
Finally, we use TransformerCPI2.0 to discover new hits for challenging drug targets, and identify new target for an existing drug based on an inverse application of the concept. Overall, this proof-of-concept study shows that the sequence-to-drug concept adds a perspective on drug design. It ...
In summary, drug repurposing can be divided into three stages: identifying the core targets of the disease (hypothesis generation), determining the efficacy of the drug through in vitro and in vivo models, and proceeding to phase II clinical trials in cases where phase I trials have yielded ade...